A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Summary

This is a Phase 2/3, randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy and safety of FP-025 in adult patients with severe to critical COVID 19 with associated ARDS.

Timeline

Start

2021-04-06

Primary completion

2022-04-18

Completion

2022-04-18

Outcome

Outcome not reported

Stopped (Enrollment): “Study stopped at interim analysis point, due to lack of study subjects to recruit.”

Drugs

Indications